Shanmugasundaram E R, Sundaram P, Srinivas K, Shanmugasundaram K R, Shankaran J R
Department of Biochemistry, University of Madras, India.
J Ethnopharmacol. 1991 Jan;31(1):85-99. doi: 10.1016/0378-8741(91)90147-6.
The plasma lipid lowering effect of modified Anna Pavala Sindhooram (APSm) was tested in 30 patients with plasma lipid abnormalities and with symptomatic ischemic heart disease (IHD) in a double-blind cross-over design. HDL2 cholesterol and total HDL cholesterol were increased during APSm therapy leading to a reduction in the coronary risk index. Plasma cholesterol, LDL and VLDL cholesterol, triglycerides, phospholipids and free fatty acids were significantly reduced during APSm therapy while withdrawal of the drug led to a slow increase in these lipids. No adverse side effects were noticed. Some patients were able to reduce their daily doses of antihypertensive and vasodilator drugs during APSm therapy.
采用双盲交叉设计，对30例血脂异常且患有症状性缺血性心脏病（IHD）的患者，测试了改良的安娜·帕瓦拉·辛杜勒姆（APSm）的降血脂效果。在APSm治疗期间，HDL2胆固醇和总HDL胆固醇增加，导致冠状动脉风险指数降低。在APSm治疗期间，血浆胆固醇、LDL和VLDL胆固醇、甘油三酯、磷脂和游离脂肪酸显著降低，而停药后这些血脂会缓慢上升。未观察到不良副作用。一些患者在APSm治疗期间能够减少其每日的抗高血压和血管扩张药物剂量。
